Omnicell (NASDAQ:OMCL) PT Raised to $41.00 at Wells Fargo & Company

Omnicell (NASDAQ:OMCL) had its price target increased by Wells Fargo & Company from $30.00 to $41.00 in a research note published on Monday, Benzinga reports. The brokerage currently has an equal weight rating on the stock.

Several other brokerages have also recently issued reports on OMCL. Barclays raised Omnicell from an “underweight” rating to an “equal weight” rating and increased their price objective for the stock from $26.00 to $39.00 in a research note on Friday, August 2nd. Bank of America increased their target price on Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. StockNews.com raised Omnicell from a “hold” rating to a “buy” rating in a research report on Thursday, October 10th. JPMorgan Chase & Co. increased their target price on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research report on Friday, August 23rd. Finally, Benchmark reaffirmed a “buy” rating and set a $48.00 target price on shares of Omnicell in a research report on Wednesday, October 9th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $41.33.

Omnicell Stock Up 0.4 %

Shares of NASDAQ:OMCL opened at $42.56 on Monday. Omnicell has a 52-week low of $25.12 and a 52-week high of $45.84. The stock has a market cap of $1.95 billion, a P/E ratio of -92.52, a price-to-earnings-growth ratio of 47.35 and a beta of 0.83. The business’s 50 day moving average is $43.19 and its 200 day moving average is $34.10. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.37. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The company had revenue of $276.80 million for the quarter, compared to analysts’ expectations of $254.41 million. During the same quarter in the prior year, the firm earned $0.29 earnings per share. Omnicell’s revenue was down 7.4% compared to the same quarter last year. Sell-side analysts predict that Omnicell will post 0.64 EPS for the current year.

Institutional Trading of Omnicell

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in shares of Omnicell by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock valued at $165,200,000 after purchasing an additional 80,312 shares during the last quarter. Mutual of America Capital Management LLC lifted its holdings in shares of Omnicell by 197.9% during the 1st quarter. Mutual of America Capital Management LLC now owns 124,600 shares of the company’s stock valued at $3,642,000 after purchasing an additional 82,774 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Omnicell by 61.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock valued at $16,240,000 after purchasing an additional 228,093 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Omnicell during the 1st quarter valued at $684,000. Finally, Illinois Municipal Retirement Fund purchased a new position in Omnicell in the 1st quarter worth $718,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.